Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology ...
Written agreement from FDA for single-arm, open-label, baseline-controlled registrational trial evaluating composite primary endpoint of improvement in CGI-I and gain of developmental milestone/skill ...
Krystal Biotech (NASDAQ:KRYS) said it has generated positive interim clinical results for its inhaled cystic fibrosis (CF) ...
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutationsKB407 transduction confirmed in all ...
$5 million tranche received under up to $20 million financing agreement IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 The initial tranche was ...
February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy ...
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...
Strategic Transaction-- The company is in "advanced stages to finalize a strategic transaction with a potential partner by year-end." FDA Alignment-- BioAtla (NASDAQ:BCAB) achieved FDA alignment on ...
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing ...
Preliminary PT-112 Phase 2 clinical outcomes in metastatic castration-resistant prostate cancer patients will be presented at the ASCO 2025 Annual Meeting NEW YORK, May 20, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback